|
Ibritumomab Tiuxetan
Product Approval Information - Licensing Action
Proper name: Ibritumomab Tiuxetan
Tradename: Zevalin
Manufacturer: IDEC Pharmaceuticals Corp, San Diego, CA, License #1235
Indication for Use: Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin’s lymphoma. The therapeutic regimen includes Rituximab, Indium-111 Ibritumomab Tiuxetan, and Yttrium-90 Ibritumomab Tiuxetan
Approval Date: 2/19/2002
Type of submission: Biologics license application
Approval Letter
(Text),
(PDF)
Label
(PDF)
Talkpaper
Last Updated: 3/6/2002
Back
to Top
Back to Index
Date created: September 24, 2003 |
|